Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066339 | 0.86 | SMN1; SMN2 (0.47) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL24429207 | 0.82 | MEN1 (0.51) | KMT2AGAASMN1; SMN2MEN1TDP1 | |
| SCHEMBL162725 | 0.81 | POLB (0.59) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL3331311 | 0.81 | HPGD (0.60) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL3183106 | 0.81 | POLB (0.59) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL12172746 | 0.81 | KDM4E (0.66) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL31432180 | 0.81 | KDM4E (0.66) | POLBKMT2AHSD17B10GAASMN1; SMN2 | |
| SCHEMBL4352870 | 0.80 | KMT2A (0.55) | KMT2AMEN1TDP1HPGDALDH1A1 | |
| SCHEMBL7204917 | 0.80 | MEN1 (0.47) | POLBKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL27271137 | 0.80 | BACE1 (0.52) | KMT2ASMN1; SMN2MEN1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | THE UNIVERSITY OF TOLEDO (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2017223160-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | AIFM1, HSPE1, COX15 | POLB 968/4885KMT2A 4789/4885HSD17B10 937/4885 |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | AIFM1, HSPE1, COX15 | POLB 968/4885KMT2A 4789/4885HSD17B10 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.